**Author details**

Vivian Gonzaga1,2\*, Bruna Policiquio1 , Cristiane Wenceslau<sup>2</sup> and Irina Kerkis1 \*

1 Laboratory of Genetics, Butantan Institute, São Paulo, SP, Brazil

2 CellAvita Ltd, Valinhos, SP, Brazil

\*Address all correspondence to: vivia\_gonzaga@hotmail.com and irina.kerkis@butantan.gov.br

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**159**

*Alternative Immune-Mediated-Based Methods in the Aplastic Anemia Treatment*

to immunosuppressive therapy in patients with aplastic anemia. Blood. 2002;**100**(4):1185-1191. DOI: 10.1182/

[8] Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;**129**(11):1428-1436. DOI: 10.1182/

[9] Ogawa S. Clonal hematopoiesis in acquired aplastic anemia. Blood. 2016;**128**:337-347. DOI: 10.1182/

[10] Broglie L, Margolis D, Medin JA. Yin and Yang of mesenchymal stem cells and aplastic anemia. World Journal of Stem Cells. 2017;**9**(12):219-226. DOI:

[11] Rad F, Ghorbani M, Mohammadi

Mesenchymal stem cell-based therapy for autoimmune diseases: Emerging roles of extracellular vesicles. Molecular Biology Reports. 2019;**46**:1533-1549. DOI: 10.1007/s11033-019-04588-y

[12] Marquez-Curtis LA, Janowska-Wieczorek A. Enhancing the migration ability of mesenchymal stromal cells by targeting the SDF-1/CXCR4 axis. BioMed Research International. 2013;**2013**. DOI: 10.1155/2013/561098

[13] Oliveira RL, Chagastelles PC, Sesterheim P, Pranke P. In vivo immunogenic response to allogeneic mesenchymal stem cells and the role of Preactivated mesenchymal stem cells Cotransplanted with allogeneic islets. Stem Cells International. 2017;**2017**.

DOI: 10.1155/2017/9824698

10.1016/j.jocit.2014.12.001

stem cells: Immunomodulatory capability and clinical potential in immune diseases. Journal of Cellular Immunotherapy. 2016;**2**:3-20. DOI:

[14] Zhao Q, Ren H, Han Z. Mesenchymal

blood-2002-01-0035

blood-2016-08-693481

blood-2016-01-636381

10.4252/wjsc.v9.i12.219

Roushandeh A, Habibi RM.

*DOI: http://dx.doi.org/10.5772/intechopen.89090*

[1] Medinger M, Drexler B, Lengerke C, Passweg J. Pathogenesis of acquired aplastic anemia and the role of the bone marrow microenvironment. Frontiers in Oncology. 2018;**8**:587. DOI: 10.3389/

[2] Marsh JCW, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, et al. Guidelines for the diagnosis and management of aplastic anaemia. British Journal of

Haematology. 2009;**147**:43-70. DOI: 10.1111/j.1365-2141.2009.07842.x

[3] Zoumbos NC, Gascon P, Djeu JY, Young NS. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proceedings of the National Academy of Sciences. 1985;**82**(1):188-192. DOI:

[4] Dubey S, Shukla P, Nityanand S. Expression of interferon-γ and tumor necrosis factor-α in bone marrow T cells and their levels in bone marrow plasma in patients with aplastic anemia. Annals of Hematology. 2005;**84**(9):572-577. DOI: 10.1007/s00277-005-1022-8

[5] Zeng W, Miyazato A, Chen G, Kajigaya S, Young NS, Maciejewski JP. Interferon-induced gene expression in CD34 cells: Identification of pathologic cytokine-specific signature profiles. Blood. 2006;**107**:167-175. DOI: 10.1182/

[6] Li JP, Zheng CL, Han ZC. Abnormal immunity and stem/progenitor cells in acquired aplastic anemia. Critical Reviews in Oncology/Hematology. 2010;**75**:79-93. DOI: 10.1016/j. critrevonc.2009.12.001

[7] Sloand E, Kim S, Maciejewski JP, Tisdale J, Follmann D, Young NS. Intracellular interferon-γ in circulating

and marrow T cells detected by flow cytometry and the response

10.1073/pnas.82.1.188

blood-2005-05-1884

fonc.2018.00587

**References**

*Alternative Immune-Mediated-Based Methods in the Aplastic Anemia Treatment DOI: http://dx.doi.org/10.5772/intechopen.89090*
